Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)

被引：0
|
作者：
Han, B. [1 ]
Fang, W. [1 ]
Chen, C. [2 ]
Zhang, W. [1 ]
Zhang, B. [1 ]
Yao, F. [1 ]
Shi, J. [1 ]
Yue, D. [3 ]
Qi, Y. [4 ]
Zhu, Z. [5 ]
Xie, J. [6 ]
机构：
[1] Shanghai Jiao Tong Univ, Affiliated Chest Hosp, Shanghai, Peoples R China
[2] Shanghai Pulm Hosp, Shanghai, Peoples R China
[3] Tianjin Med Univ, Canc Inst Hosp, Tianjin, Peoples R China
[4] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[6] Putian Coll, Affiliated Hosp, Putian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; high-grade patterns; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.27-09
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [1] Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
    Wu, L.
    Jia, H. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1649 - S1649
  • [2] Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors
    Wu, Q.
    Ni, M.
    Xue, F.
    Wu, X.
    Jiang, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S545 - S545
  • [3] Aumolertinib as Adjuvant Therapy in Resectable I-III EGFR-Mutant NSCLC : Also Effective in Patients with High-Risk Relapse Factors
    Yao, J.
    Song, W.
    Wang, R.
    Gu, S.
    Zhang, Q.
    Zou, J. L.
    Zhong, C. H.
    Qu, R. C.
    Chen, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S120 - S120
  • [4] Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
    Fang, W. F.
    Bu, Q.
    Wang, Q. M.
    Zhao, W. H.
    Wang, L. P.
    Dong, X. R.
    Chen, P. F.
    Wen, Z. B.
    Jia, J.
    Jiang, G. M.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S333 - S334
  • [5] Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
    Fang, W.
    Bu, Q.
    Wang, Q.
    Zhao, W.
    Wang, L.
    Dong, X.
    Chen, P.
    Wen, Z.
    Jia, J.
    Jiang, G.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1588
  • [6] Adjuvant Aumolertinib in Resected Stage I EGFRMutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions
    Huang, C. B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S540 - S541
  • [7] Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients
    Yue, D.
    Xu, S.
    Wang, Q.
    Li, X.
    Shen, Y.
    Zhao, H.
    Chen, C.
    Mao, W.
    Liu, W.
    Liu, J.
    Zhang, L.
    Ma, H.
    Li, Q.
    Yang, Y.
    Liu, Y.
    Chen, H.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1789 - S1789
  • [8] Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components
    Han, B.
    Fang, V.
    Yao, F.
    Song, P.
    Yue, D.
    Qi, Y.
    Zhang, B.
    Zhang, W.
    Zhang, Y.
    Tan, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S981 - S981
  • [9] SAFETY AND EFFICACY OF ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
    Lolli, Ivan
    Divella, Rosa
    Manzillo, Elvira Foglia
    Ercolino, Letizia
    Ronco, Michele
    Troccoli, Vito
    Occhiogrosso, Giuseppe
    Troccoli, Giuseppe
    ANNALS OF ONCOLOGY, 2004, 15 : 86 - 86
  • [10] Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?
    Segev, Y.
    Ismiil, N.
    McVeyi, R.
    Covens, A.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (06) : 633 - 636
12345